Open AccessDoes the 5-Aminosalicylate Concentration Correlate with the Efficacy of Oral 5-Aminosalicylate and Predict Response in Patients with Inflammatory Bowel Disease? A Systematic Review
Author(s) -
Maartje M van de Meeberg,
Johannes P D Schultheiss,
Bas Oldenburg,
Herma H. Fidder,
Alwin D. R. Huitema
Publication year - 2019
Publication title -
digestion
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.882
H-Index - 75
eISSN - 1421-9867
pISSN - 0012-2823
DOI - 10.1159/000499331
Subject(s) - mesalazine , medicine , ulcerative colitis , gastroenterology , inflammatory bowel disease , therapeutic effect , feces , aminosalicylic acid , drug , disease , colitis , randomized controlled trial , urine , pharmacology , paleontology , biology
Oral 5-aminosalicylic acid (5-ASA, mesalazine) is the first choice therapeutic agent for treating mild-to-moderate ulcerative colitis (UC). Unfortunately a significant group of patients fail to respond. Therapeutic drug monitoring might help to maintain or induce remission by providing a tool for optimization of 5-ASA therapy. However, plasma and urine concentrations of 5-ASA reflect systemic uptake and are not useful to evaluate therapeutic effect.